A Beacon in the Winter: Why Bispecific Antibodies Are Driving the Biggest Deals of 2025

Amid a global slowdown in biopharma dealmaking, capital has shown an unprecedented degree of concentration—propelling bispecific antibodies to the forefront of high-value transactions in 2025. When overall deal volume fell to its lowest level since 2016, the most substantial licensing agreements and merger and acquisition (M&A) transactions continued to cluster around multispecific antibody assets.

In a recent Nature commentary, Dr. Andrew Marshall noted that the three highest-value licensing deals and the second-largest merger announced year to date are all directly linked to bispecific antibodies. This preference reflects more than a short-term cyclical rebound. Instead, it signals a structural inflection point in the industry, shaped by converging pressures from patent expirations, the need for differentiated clinical efficacy, and persistent research and development (R&D) cost constraints. Increasingly, capital appears to be aligning with modalities that promise a meaningful clinical step forward through dual-targeting strategies.

Less Volume, More Value: Bispecific Antibodies as a Structural Bright Spot

The biopharma deal landscape in 2025 has contracted markedly. By October, just 215 transactions had been announced across the industry—the lowest figure in nearly eight years. Yet this decline in activity has not translated into diminished deal value. On the contrary, capital deployment has become more selective. In oncology, the average value of individual licensing agreements rose by more than 30% year on year, highlighting a pronounced concentration effect.

Within this increasingly selective environment, bispecific antibodies have defied the broader downturn to emerge as a focal point of business development. Six of the top 20 licensing deals involved bispecific or multispecific formats, while several of the year’s largest mergers centered on T-cell engager (TCE) platforms. The fact that bispecifics continue to attract high-value transactions, even in the so-called “capital winter,” underscores a deeper structural shift in how strategic value is being assessed across the industry.

Number of biopharma R&D deals by therapeutic area

Clinical Proof Accumulates as Bispecifics Mature

The movement of bispecific antibodies toward mainstream acceptance has been underpinned by a series of clinically meaningful validation events over the past several years. A key milestone came with Johnson & Johnson’s VEGA Phase IIa trial in 2022, which demonstrated for the first time in humans that dual inhibition of IL-23 and TNF-α could achieve superior efficacy compared with monotherapy in ulcerative colitis. This readout provided clear proof-of-principle that synergistic targeting of two validated immunology pathways could offer an expanded therapeutic window, catalyzing broader interest in rational target-pairing strategies.

Momentum continued with the regulatory approval of Amgen’s DLL3×CD3 T-cell engager, tarlatamab, marking a breakthrough for TCEs in solid tumors and extending the modality beyond hematologic malignancies. In parallel, the rapid emergence of trispecific antibody programs reflects a growing appetite for mechanism stacking—aimed at enhancing efficacy, widening therapeutic windows, and mitigating resistance through coordinated pathway modulation.

Importantly, this evolution is not confined to oncology. More than 40% of recent bispecific and multispecific antibody deals have targeted autoimmune and inflammatory diseases, often through bispecific or trispecific T-cell engager strategies directed at pathogenic B-cell markers such as CD19 and CD20. Together, these developments point to bispecific antibodies transitioning from an experimental innovation into a broadly applicable therapeutic strategy.

Mechanism of action of tarlatamab

2025 Deals: Bispecifics and Multispecifics Go Mainstream

The 2025 licensing landscape clearly shows that bispecific and multispecific antibodies are rapidly becoming a dominant force in drug development. Innovent and Takeda partnered on a PD-1×IL-2 bispecific deal worth $11.4 billion, while BioNTech advanced a PD-L1×VEGF-A bispecific collaboration with BMS. Other deals, including 3SBio and Pfizer’s PD-1×VEGF bispecific and Querns and Roche’s TSLP×IL-33 bispecific, were also actively executed. Meanwhile, companies like Xilio, IGI Therapeutics, and Simcere Zaiming partnered with AbbVie on multispecific programs such as CD3×PSMA and CD38×BCMA×CD3.

These transactions span the full spectrum from preclinical to Phase III, with individual deal values exceeding $1billion. They underscore the bispecific development capabilities of biotechs like Innovent and BioNTech, while highlighting the strategic focus of major pharma players including Takeda, Pfizer, and Roche on the bispecific/multispecific antibody space. Collectively, these deals demonstrate that bispecifics and multispecifics have evolved from an innovative niche into a central pillar of modern drug development.

Top 10 multispecific antibody deals in 2025

Mainstreaming Bispecifics: Rising Complexity Across the Development Stack

As bispecific antibodies move toward the center of drug development strategies, the challenges associated with their advancement are increasing nonlinearly. Each stage—from molecular design and functional validation to CMC development for IND submission—presents hurdles that exceed those encountered with conventional monoclonal antibodies. Engineering complexities related to chain pairing, structural stability, and aggregation control are amplified, particularly in trispecific formats.

Functional characterization further demands coordinated evaluation of dual-target synergy, immune cell activation profiles, and cytokine release syndrome risk, requiring robust, quantitative, and highly reproducible assay systems. Downstream, CMC development imposes more stringent requirements on impurity control, batch-to-batch consistency, and scalable manufacturing processes.

Together, these factors suggest that the next phase of competition in the bispecific landscape will be defined less by isolated platform innovations and more by integrated, end-to-end R&D capabilities capable of supporting clinical translation at scale.

ACRO Comprehensive Solutions for Bispecific Antibody Development

In line with these trends, ACROBiosystems provides comprehensive solutions covering the full bispecific antibody R&D process. Our portfolio includes high-consistency target proteins, stably expressing cell lines, application-specific assay kits, and supporting analytical services. Collectively, these tools support key stages from early target discovery and validation, candidate screening and functional evaluation, to CMC development and quality control, helping accelerate the development and translation of innovative bispecific therapies.

Sources

1. https://doi.org/10.1038/d43747-025-00111-4

2. https://dx.doi.org/10.21037/tlcr-23-230